South Korea's Celltrion has already filed its rituximab biosimilar in Europe in November. Sandoz's biosimilar adds to a long list of biosimilars under review in Europe, including two versions of ...
Pfizer’s biosimilar of Roche’s blockbuster blood cancer and inflammatory diseases drug rituximab has succeeded in a late-stage trial comparing it with the original drug. The company said the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback